1 week Ago By Defense World Staff
Prudential Financial Inc. grew its position in Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) by 71.
3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 109,105 shares of the company’s stock after acquiring an additional 45,400 shares during the period. Prudential Financial Inc.
owned 0.27% of Solid Biosciences worth $436,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also modified their holdings of SLDB.
China Universal Asset Management Co. Ltd. bought a new position in Solid Biosciences in the 4th quarter valued at $34,000.
The Manufacturers Life Insurance Company bought a new position in shares of Solid Biosciences in the third quarter valued at about $71,000. Sei Investments Co. bought a new position in shares of Solid Biosciences in the fourth quarter valued at about $52,000.
MetLife Investment Management LLC lifted its position in Solid Biosciences by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock worth $95,000 after buying an additional 7,719 shares in the last quarter.
Finally, XTX Topco Ltd bought a new stake in Solid Biosciences during the 3rd quarter worth about $121,000. 81.46% of the stock is owned by institutional investors and hedge funds.
Solid Biosciences Stock PerformanceShares of SLDB opened at $2.74 on Thursday. The stock has a 50 day simple moving average of $4.
39 and a 200 day simple moving average of $4.84. Solid Biosciences Inc.
has a 52-week low of $2.48 and a 52-week high of $11.28.
The firm has a market capitalization of $212.33 million, a PE ratio of -0.90 and a beta of 2.
07. Analyst Ratings ChangesA number of brokerages have recently issued reports on SLDB. Wedbush began coverage on shares of Solid Biosciences in a research report on Friday, December 13th.
They set an “outperform” rating and a $16.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $16.
00 price objective on shares of Solid Biosciences in a research report on Friday, March 7th. HC Wainwright boosted their target price on Solid Biosciences from $16.00 to $20.
00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Truist Financial began coverage on Solid Biosciences in a report on Wednesday, January 8th. They issued a “buy” rating and a $16.
00 price target on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on Solid Biosciences from $12.
00 to $11.00 and set an “overweight” rating for the company in a report on Thursday, March 13th. Eight equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock.
Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.67.
Check Out Our Latest Report on SLDBAbout Solid Biosciences (Free Report)Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.See AlsoFive stocks we like better than Solid BiosciencesDo Real Estate Investment Trusts Deserve a Place in Your Portfolio?Quantum Computing: The $6.
5 Billion Opportunity You Can’t IgnoreFind and Profitably Trade Stocks at 52-Week LowsAre Tariffs Threatening Disney’s Comeback Story?Want to Profit on the Downtrend? Downtrends, Explained.Is Alphabet a Generational Buying Opportunity at These Levels?Want to see what other hedge funds are holding SLDB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solid Biosciences Inc.
(NASDAQ:SLDB – Free Report)..
